Matthew Henn
Chief Tech/Sci/R&D Officer chez SERES THERAPEUTICS, INC.
Fortune : 49 099 $ au 31/03/2024
Profil
Matthew R.
Henn is currently the Chief Scientific Officer & Executive VP at Seres Therapeutics, Inc. He previously worked as a Director at Viral Genomics, Inc. and as a Director-Viral Genomics at The Broad Institute, Inc. Dr. Henn holds a doctorate degree from the University of California, Berkeley and an undergraduate degree from the University of New Hampshire.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
SERES THERAPEUTICS INC
0,04% | 16/02/2024 | 63 436 ( 0,04% ) | 49 099 $ | 31/03/2024 |
Postes actifs de Matthew Henn
Sociétés | Poste | Début |
---|---|---|
SERES THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 07/02/2019 |
Anciens postes connus de Matthew Henn
Sociétés | Poste | Fin |
---|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2012 |
Viral Genomics, Inc. | Director/Board Member | - |
Formation de Matthew Henn
University of California, Berkeley | Doctorate Degree |
University of New Hampshire | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
SERES THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Viral Genomics, Inc. | |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |